Browsing by Autor "Michael A. Patton"
Now showing 1 - 1 of 1
- Results Per Page
- Sort Options
Item type: Item , Efficacy, Immunogenicity, and Safety of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Vaccine in Older Adults Over 2 RSV Seasons(Oxford University Press, 2025) Edward E. Walsh; Daniel Eiras; John Woodside; Qin Jiang; Michael A. Patton; Gonzalo Pérez Marc; Conrado J. Llapur; Mika Rämet; Yasushi Fukushima; Nazreen HussenHigh RSV neutralizing titers were observed 1 month after RSVpreF vaccination in persons aged ≥60 years, with similarly robust responses across subgroups. These immune responses corresponded with high RSVpreF VE against RSV-associated LRTI. RSVpreF had a favorable safety profile over 2 seasons. Clinical Trials Registration. NCT05035212; EudraCT, 2021-003693-31.